pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
TROP-2 · news · pharmadog
← back to TROP-2
News · TROP-2
96
stories
15h
Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
fiercebiotech
6d
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
biospace
22d
J&J pharma leader to retire; Krystal slumps on gene therapy miss
biopharma dive
22d
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
22d
Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
fiercebiotech
24d
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
28d
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
Jul 15, 26
Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
biospace
Jun 9, 26
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
biopharma dive
Jun 9, 26
Gilead and Merck’s latest trial success and flop
stat
May 29, 26
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
biopharma dive
May 18, 26
Merck ADC, licensed from China, hits mark in first big global trial
biopharma dive
May 14, 26
Emerging Biomarkers in NSCLC: TROP2 Scoring and MTAP Loss
onclive
May 13, 26
Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practice
onclive
May 13, 26
FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
onclive
May 13, 26
FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma
onclive
May 13, 26
Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML
onclive
May 13, 26
Future Directions in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Personalized Treatment Decision-Making in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Future Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Safety and Toxicity Management in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Combination and Sequencing Strategies in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Patient Selection for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Alpha-Emitting Therapies in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Combination Radiopharmaceutical Approaches in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Dr Bockorny on the Rationale for Targeting CCR8 in Solid Tumors
onclive
May 13, 26
UCSF Receives Major Gift to Advance Research and Modernization
onclive
May 13, 26
CLL-321 Trial Efficacy and Safety Results Analysis
onclive
← prev
page 1 of 4
next →
